Literature DB >> 18094005

Lung carcinomas with a basaloid pattern: a study of 90 cases focusing on their poor prognosis.

D Moro-Sibilot1, S Lantuejoul, S Diab, N Moulai, A Aubert, J F Timsit, C Brambilla, P Y Brichon, E Brambilla.   

Abstract

Lung carcinoma with a basaloid pattern (BC) is classified as either a basaloid variant of squamous cell carcinoma (SCC) or as variant of large cell carcinoma (LCC) depending on the presence of a squamous component. In a previous study of 37 cases, the present authors showed that BC presented with a shorter median and overall survival. In order to confirm its clinical significance in a larger series, 90 BC, including 46 basaloid variants of LCC and 44 basaloid variants of SCC, were compared with 1,328 other nonsmall cell lung carcinoma (NSCLC) with regard to clinical features and survival. The survival of basaloid variants of LCC and SCC was comparable. Median and overall survival were significantly lower for BC than for NSCLC in stage I-II patients, with a median survival of 29 and 49 months, respectively, and 5-yr survival rates of 27 and 44% for BC and NSCLC. When disease-specific survival was considered, BC had a shorter survival than both NSCLC and SCC. Basaloid pattern confers a poor prognosis in nonsmall cell lung carcinoma, especially in stage I-II patients, suggesting that lung carcinoma with a basaloid pattern is not only a variant of squamous cell carcinoma or large cell carcinoma, but is a unique entity with a significantly poor prognosis.

Entities:  

Mesh:

Year:  2007        PMID: 18094005     DOI: 10.1183/09031936.00058507

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  19 in total

Review 1.  [Lung cancer. Developments, concepts and preview of the new WHO classification].

Authors:  I Petersen; A Warth
Journal:  Pathologe       Date:  2014-11       Impact factor: 1.011

2.  Targeted therapies for locally advanced or metastatic squamous cell carcinoma of the lung.

Authors:  Thomas E Stinchcombe
Journal:  Curr Treat Options Oncol       Date:  2013-12

3.  Reevaluation and reclassification of resected lung carcinomas originally diagnosed as squamous cell carcinoma using immunohistochemical analysis.

Authors:  Kyuichi Kadota; Jun-ichi Nitadori; Natasha Rekhtman; David R Jones; Prasad S Adusumilli; William D Travis
Journal:  Am J Surg Pathol       Date:  2015-09       Impact factor: 6.394

4.  Basaloid Squamous Cell Carcinoma of the Lung Associated With Syndrome of Inappropriate Antidiuretic Hormone Secretion.

Authors:  Ashraf Abugroun; Fatima Ahmed; Toni-Denise Espina; Alvaro Altamirano Ufion
Journal:  World J Oncol       Date:  2017-12-28

5.  Late recurrence of basaloid carcinoma initially treated as a small cell lung cancer.

Authors:  Vladimir Shumaster; Jason W Bae; Scott N Gettinger; Guoping Cai; Anthony W Kim
Journal:  J Thorac Dis       Date:  2013-04       Impact factor: 2.895

Review 6.  Current status of research and treatment for non-small cell lung cancer in never-smoking females.

Authors:  Shin Saito; Fernando Espinoza-Mercado; Hui Liu; Naohiro Sata; Xiaojiang Cui; Harmik J Soukiasian
Journal:  Cancer Biol Ther       Date:  2017-05-11       Impact factor: 4.742

7.  Spread through Air Spaces (STAS) Is an Independent Predictor of Recurrence and Lung Cancer-Specific Death in Squamous Cell Carcinoma.

Authors:  Shaohua Lu; Kay See Tan; Kyuichi Kadota; Takashi Eguchi; Sarina Bains; Natasha Rekhtman; Prasad S Adusumilli; William D Travis
Journal:  J Thorac Oncol       Date:  2016-09-28       Impact factor: 15.609

8.  Comprehensive histologic assessment helps to differentiate multiple lung primary nonsmall cell carcinomas from metastases.

Authors:  Nicolas Girard; Charuhas Deshpande; Christopher Lau; David Finley; Valerie Rusch; William Pao; William D Travis
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

9.  PD-L1 expression in basaloid squamous cell lung carcinoma: Relationship to PD-1+ and CD8+ tumor-infiltrating T cells and outcome.

Authors:  Marius Ilie; Alexander T Falk; Catherine Butori; Emmanuel Chamorey; Christelle Bonnetaud; Elodie Long; Sandra Lassalle; Katia Zahaf; Nicolas Vénissac; Jérôme Mouroux; Charlotte Cohen; Elisabeth Brambilla; Charles Hugo Marquette; Véronique Hofman; Paul Hofman
Journal:  Mod Pathol       Date:  2016-08-26       Impact factor: 7.842

10.  SOX2 is an oncogene activated by recurrent 3q26.3 amplifications in human lung squamous cell carcinomas.

Authors:  Thomas Hussenet; Soraya Dali; Julien Exinger; Ben Monga; Bernard Jost; Doulaye Dembelé; Nadine Martinet; Christelle Thibault; Joerg Huelsken; Elisabeth Brambilla; Stanislas du Manoir
Journal:  PLoS One       Date:  2010-01-29       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.